Literature DB >> 24422571

Retinoblastoma: saving life with vision.

David H Abramson1.   

Abstract

Retinoblastoma has gone from >95% mortality to >95% survival in the past 100 years. Once enucleation techniques were perfected, the majority of children survived, but without the eye (or vision in that eye). Over the past 100 years, progressively better techniques have been developed for salvaging vision without sacrificing patient survival. Presently, 99% of children treated at our center survive their cancer, >99% retain at least one eye, and >90% retain normal vision in at least one eye. The introduction of ophthalmic artery chemosurgery has been the most dramatic, non-radiation-based mode to maximally preserve vision.

Entities:  

Mesh:

Year:  2014        PMID: 24422571     DOI: 10.1146/annurev-med-061312-123455

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  36 in total

1.  The analysis of posterior segment findings in term and premature infants using RetCam images.

Authors:  Huseyin Gursoy; Mustafa Deger Bilgec; Nazmiye Erol; Hikmet Basmak; Ertugrul Colak
Journal:  Int Ophthalmol       Date:  2017-08-05       Impact factor: 2.031

Review 2.  Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma.

Authors:  Emily S Tonorezos; Danielle Novetsky Friedman; Dana Barnea; Machteld I Bosscha; Guillermo Chantada; Charlotte J Dommering; Pim de Graaf; Ira J Dunkel; Armida W M Fabius; Jasmine H Francis; Mary-Louise C Greer; Ruth A Kleinerman; Wijnanda A Kors; Suzanne Laughlin; Annette C Moll; Lindsay M Morton; Petra Temming; Margaret A Tucker; Flora E van Leeuwen; Michael F Walsh; Kevin C Oeffinger; David H Abramson
Journal:  Ophthalmology       Date:  2020-05-15       Impact factor: 12.079

3.  Ophthalmic artery chemosurgery for eyes with advanced retinoblastoma.

Authors:  David H Abramson; Armida W M Fabius; Jasmine H Francis; Brian P Marr; Ira J Dunkel; Scott E Brodie; Anna Escuder; Y Pierre Gobin
Journal:  Ophthalmic Genet       Date:  2017-01-17       Impact factor: 1.803

4.  Nanoparticle-aided Radiotherapy for Retinoblastoma and Choroidal Melanoma.

Authors:  Yucel Altundal; Erno Sajo; G Mike Makrigiorgos; Ross I Berbeco; Wilfred Ngwa
Journal:  IFMBE Proc       Date:  2015

Review 5.  Management of retinoblastoma in children: current status.

Authors:  Guillermo Chantada; Paula Schaiquevich
Journal:  Paediatr Drugs       Date:  2015-06       Impact factor: 3.022

Review 6.  Establishment of an Orthotopic Xenograft Mice Model of Retinoblastoma Suitable for Preclinical Testing.

Authors:  Nathalie Cassoux; Aurélie Thuleau; Franck Assayag; Isabelle Aerts; Didier Decaudin
Journal:  Ocul Oncol Pathol       Date:  2015-04-09

7.  The Effect of Ophthalmic Artery Chemosurgery on Immune Function in Retinoblastoma Patients: A Single Institution Retrospective Analysis.

Authors:  Cheryl Fischer; Mary Petriccione; Stephanie Vitolano; Edith Guarini; Mary Elizabeth Davis; Ira J Dunkel
Journal:  J Pediatr Hematol Oncol       Date:  2017-10       Impact factor: 1.289

8.  The technique of superselective ophthalmic artery chemotherapy for retinoblastoma: The Garrahan Hospital experience.

Authors:  Flavio Requejo; Juan Marelli; Agustin Ruiz Johnson; Claudia Sampor; Guillermo Chantada
Journal:  Interv Neuroradiol       Date:  2017-11-09       Impact factor: 1.610

9.  Clinical evaluation of RB1 genetic testing reveals novel mutations in Vietnamese patients with retinoblastoma.

Authors:  Chinh Quoc Hoang; Hong-Quan Duong; Nguyen Thanh Nguyen; Sy Anh Hao Nguyen; Cuong Nguyen; Bo Duy Nguyen; Lan Tuyet Phung; Dung Thuy Nguyen; Chau Thi Minh Pham; Trang Le Doan; Mai Hoang Tran
Journal:  Mol Clin Oncol       Date:  2021-07-03

10.  Metastases and death rates after primary enucleation of unilateral retinoblastoma in the USA 2007-2017.

Authors:  Jonathan E Lu; Jasmine H Francis; Ira J Dunkel; Carol L Shields; Michael D Yu; Jesse L Berry; Kaitlin Kogachi; Alison H Skalet; Audra K Miller; Pranav R Santapuram; Anthony B Daniels; David H Abramson
Journal:  Br J Ophthalmol       Date:  2018-10-25       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.